Form 4 - Statement of changes in beneficial ownership of securities
SEC Form 4
| FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 |
| |||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
| Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | |||||||||||||||||
1. Name and Address of Reporting Person*
| 2. Issuer Name and Ticker or Trading Symbol RECURSION PHARMACEUTICALS, INC. [ RXRX ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
| |||||||||||||||||||||||
| 3. Date of Earliest Transaction (Month/Day/Year) 06/03/2024 | |||||||||||||||||||||||||
| 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line)
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Class A Common Stock | 06/03/2024 | A(1) | 13,097 | A | $0 | 72,186 | D | |||
| Class A Common Stock | 1,422,048 | I | By Dean Li and Ruth Li Revocable Trust | |||||||
| Class A Common Stock | 1,269,796 | I | By Dean Y. Li GRAT | |||||||
| Class A Common Stock | 421,000 | I | By Dean Y. Li 2021 Family Trust | |||||||
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Stock Option (Right to Buy) | $8.59 | 06/03/2024 | A | 26,193 | (2) | 06/03/2034 | Class A Common Stock | 26,193 | $0 | 26,193 | D | ||||
| Explanation of Responses: |
| 1. Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 3, 2025 or the day prior to the Issuer's 2025 annual meeting of stockholders, subject to Reporting Person's continued service to the Issuer. |
| 2. The shares subject to this option will vest and become exercisable on the earlier of June 3, 2025 or the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. |
| Remarks: |
| /s/Jonathan Golightly, attorney-in-fact | 06/05/2024 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
Recursion Pharmaceuticals (NASDAQ:RXRX)
Historical Stock Chart
From May 2024 to Jun 2024
Recursion Pharmaceuticals (NASDAQ:RXRX)
Historical Stock Chart
From Jun 2023 to Jun 2024
 | {{bbMessage.M_Alias}}{{bbMessage.MSG_Date}}{{bbMessage.HowLongAgo}}{{bbMessage.MSG_ID}}{{bbMessage.MSG_Subject}} |
Loading Messages....
Recursion Pharmaceuticals Inc News
Loading Messages....
`,data() {return {tabs: [] };},created() {this.tabs = this.$children;},methods: {selectTab(selectedTab) {this.tabs.forEach(tab => {tab.isActive = (tab.name == selectedTab.name);});}}});Vue.component('tab', {template: `
`,props: {name: { required: true },selected: { default: false}},data() {return {isActive: false};},computed: {href() {return '#' + this.name.toLowerCase().replace(/ /g, '-');}},mounted() {this.isActive = this.selected;}});Vue.component('newslist', {template: `
FEATURED
•{{ article.source }} • {{ article.date}} {{article.time}}
`,props: {source: { required: true },rawarticles: { required: true },limit: { default: 12 }},methods: {processData: function(articles){if(articles.length > this.limit){articles = articles.slice(0, this.limit);}this.articles = articles;this.loaded = true;Vue.nextTick(function(){});},stripRedudancies: function(articles){return _.uniqBy(articles, "headline");}},data() {return {loaded: false,articles: []};},mounted() {this.processData(this.rawarticles);}});new Vue({el: '#nw-news-widget',data: {loaded: false,availableTabs: {"Press Releases": [{"headline":"Form 4 - Statement of changes in beneficial ownership of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93994318\/form-4-statement-of-changes-in-beneficial-owners","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1717625551,"date":"Wed Jun 05, 2024 ","time":"6:12 PM (3 hours ago)","full_date":"June 5, 2024 6:12 PM","post_time":"3 hours ago","article_id":93994318,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 4 - Statement of changes in beneficial ownership of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93994315\/form-4-statement-of-changes-in-beneficial-owners","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1717625520,"date":"Wed Jun 05, 2024 ","time":"6:12 PM (3 hours ago)","full_date":"June 5, 2024 6:12 PM","post_time":"3 hours ago","article_id":93994315,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 4 - Statement of changes in beneficial ownership of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93994314\/form-4-statement-of-changes-in-beneficial-owners","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1717625503,"date":"Wed Jun 05, 2024 ","time":"6:11 PM (3 hours ago)","full_date":"June 5, 2024 6:11 PM","post_time":"3 hours ago","article_id":93994314,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 4 - Statement of changes in beneficial ownership of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93994312\/form-4-statement-of-changes-in-beneficial-owners","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1717625485,"date":"Wed Jun 05, 2024 ","time":"6:11 PM (3 hours ago)","full_date":"June 5, 2024 6:11 PM","post_time":"3 hours ago","article_id":93994312,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 144 - Report of proposed sale of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93992091\/form-144-report-of-proposed-sale-of-securities","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1717605034,"date":"Wed Jun 05, 2024 ","time":"12:30 PM (9 hours ago)","full_date":"June 5, 2024 12:30 PM","post_time":"9 hours ago","article_id":93992091,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 4 - Statement of changes in beneficial ownership of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93975312\/form-4-statement-of-changes-in-beneficial-owners","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1717453901,"date":"Mon Jun 03, 2024 ","time":"6:31 PM (2 days ago)","full_date":"June 3, 2024 6:31 PM","post_time":"June 03 2024","article_id":93975312,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Recursion to Participate in Upcoming Investor Conferences","short_text":"SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...","one_line_short_text":"SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93970629\/recursion-to-participate-in-upcoming-investor-conf","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1717419600,"date":"Mon Jun 03, 2024 ","time":"9:00 AM (3 days ago)","full_date":"June 3, 2024 9:00 AM","post_time":"June 03 2024","article_id":93970629,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Form 4 - Statement of changes in beneficial ownership of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93954968\/form-4-statement-of-changes-in-beneficial-owners","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1717108884,"date":"Thu May 30, 2024 ","time":"6:41 PM (6 days ago)","full_date":"May 30, 2024 6:41 PM","post_time":"May 30 2024","article_id":93954968,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 144 - Report of proposed sale of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93953713\/form-144-report-of-proposed-sale-of-securities","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1717099428,"date":"Thu May 30, 2024 ","time":"4:03 PM (6 days ago)","full_date":"May 30, 2024 4:03 PM","post_time":"May 30 2024","article_id":93953713,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool","short_text":"SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature...","one_line_short_text":"SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93944986\/power-of-recursion-os-on-display-at-genome-scale-i","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1717010857,"date":"Wed May 29, 2024 ","time":"3:27 PM (1 week ago)","full_date":"May 29, 2024 3:27 PM","post_time":"May 29 2024","article_id":93944986,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93925841\/form-defa14a-additional-definitive-proxy-solicit","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1716582909,"date":"Fri May 24, 2024 ","time":"4:35 PM (2 weeks ago)","full_date":"May 24, 2024 4:35 PM","post_time":"May 24 2024","article_id":93925841,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93925785\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1716582690,"date":"Fri May 24, 2024 ","time":"4:31 PM (2 weeks ago)","full_date":"May 24, 2024 4:31 PM","post_time":"May 24 2024","article_id":93925785,"source_id":"edgar2","media_url":null,"press_release":true}],"All News": [{"headline":"Form 4 - Statement of changes in beneficial ownership of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93994318\/form-4-statement-of-changes-in-beneficial-owners","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1717625551,"date":"Wed Jun 05, 2024 ","time":"6:12 PM (3 hours ago)","full_date":"June 5, 2024 6:12 PM","post_time":"3 hours ago","article_id":93994318,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 4 - Statement of changes in beneficial ownership of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93994315\/form-4-statement-of-changes-in-beneficial-owners","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1717625520,"date":"Wed Jun 05, 2024 ","time":"6:12 PM (3 hours ago)","full_date":"June 5, 2024 6:12 PM","post_time":"3 hours ago","article_id":93994315,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 4 - Statement of changes in beneficial ownership of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93994314\/form-4-statement-of-changes-in-beneficial-owners","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1717625503,"date":"Wed Jun 05, 2024 ","time":"6:11 PM (3 hours ago)","full_date":"June 5, 2024 6:11 PM","post_time":"3 hours ago","article_id":93994314,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 4 - Statement of changes in beneficial ownership of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93994312\/form-4-statement-of-changes-in-beneficial-owners","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1717625485,"date":"Wed Jun 05, 2024 ","time":"6:11 PM (3 hours ago)","full_date":"June 5, 2024 6:11 PM","post_time":"3 hours ago","article_id":93994312,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 144 - Report of proposed sale of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93992091\/form-144-report-of-proposed-sale-of-securities","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1717605034,"date":"Wed Jun 05, 2024 ","time":"12:30 PM (9 hours ago)","full_date":"June 5, 2024 12:30 PM","post_time":"9 hours ago","article_id":93992091,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 4 - Statement of changes in beneficial ownership of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93975312\/form-4-statement-of-changes-in-beneficial-owners","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1717453901,"date":"Mon Jun 03, 2024 ","time":"6:31 PM (2 days ago)","full_date":"June 3, 2024 6:31 PM","post_time":"June 03 2024","article_id":93975312,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Recursion to Participate in Upcoming Investor Conferences","short_text":"SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...","one_line_short_text":"SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93970629\/recursion-to-participate-in-upcoming-investor-conf","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1717419600,"date":"Mon Jun 03, 2024 ","time":"9:00 AM (3 days ago)","full_date":"June 3, 2024 9:00 AM","post_time":"June 03 2024","article_id":93970629,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Form 4 - Statement of changes in beneficial ownership of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93954968\/form-4-statement-of-changes-in-beneficial-owners","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1717108884,"date":"Thu May 30, 2024 ","time":"6:41 PM (6 days ago)","full_date":"May 30, 2024 6:41 PM","post_time":"May 30 2024","article_id":93954968,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 144 - Report of proposed sale of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93953713\/form-144-report-of-proposed-sale-of-securities","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1717099428,"date":"Thu May 30, 2024 ","time":"4:03 PM (6 days ago)","full_date":"May 30, 2024 4:03 PM","post_time":"May 30 2024","article_id":93953713,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool","short_text":"SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature...","one_line_short_text":"SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93944986\/power-of-recursion-os-on-display-at-genome-scale-i","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1717010857,"date":"Wed May 29, 2024 ","time":"3:27 PM (1 week ago)","full_date":"May 29, 2024 3:27 PM","post_time":"May 29 2024","article_id":93944986,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93925841\/form-defa14a-additional-definitive-proxy-solicit","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1716582909,"date":"Fri May 24, 2024 ","time":"4:35 PM (2 weeks ago)","full_date":"May 24, 2024 4:35 PM","post_time":"May 24 2024","article_id":93925841,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/recursion-pharmaceuticals-RXRX\/stock-news\/93925785\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1716582690,"date":"Fri May 24, 2024 ","time":"4:31 PM (2 weeks ago)","full_date":"May 24, 2024 4:31 PM","post_time":"May 24 2024","article_id":93925785,"source_id":"edgar2","media_url":null,"press_release":true}],"Preferred Contributors": ""}},created: function () {this.loaded = true;Vue.nextTick(function(){});}});});
More Recursion Pharmaceuticals Inc News Articles
